期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
The CRAFITY score can identify patients with hepatocellular carcinoma showing poor response to treatment with atezolizumab and bevacizumab
1
作者 Sabine Lieb Sebastian Ebel +2 位作者 Daniel Seehofer Thomas Berg florian van bommel 《Hepatobiliary Surgery and Nutrition》 SCIE 2023年第1期148-150,共3页
With great interest we have read the comment of Dr.Khakoo on the recently published CRAFITY score for the prediction of response to anti-programmed death(ligand)1[PD-(L)1]-based immunotherapy in patients with unresect... With great interest we have read the comment of Dr.Khakoo on the recently published CRAFITY score for the prediction of response to anti-programmed death(ligand)1[PD-(L)1]-based immunotherapy in patients with unresectable hepatocellular carcinoma(HCC)(1). 展开更多
关键词 PATIENTS HEPATOCELLULAR carcinoma
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部